Chief Executive Officer
Dr. Ang brings experience as a senior biotech executive and is formerly a physician, venture capitalist and strategy consultant. Prior to Vor, Dr. Ang was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company prior to…
Chief Scientific Officer
Dr. Tirtha Chakraborty brings expertise in both hematology and genetic engineering to his role as Chief Scientific Officer. He formerly served as Vor’s Vice President and Head of Research. Before joining Vor, Dr. Chakraborty was Vice President of Cell Therapy Research at Sana Biotechnology….
Head of Business Development
Dr. Hilary Eaton brings cell and gene therapy business development and corporate strategy experience to Vor. Most recently before Vor, Dr. Eaton held a business development role at Editas Medicine, where she led a variety of key transactions. Prior to Editas, Dr. Eaton was…
Chief Financial Officer
Dr. Nathan Jorgensen brings a comprehensive background of buy-side, sell-side, consulting, and scientific experience to his new role at Vor. At QIA, the sovereign wealth fund of the State of Qatar, he spearheaded biotechnology and pharmaceutical investment efforts, which included opportunities in public, private,…
Chief Commercial Officer
John King is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor, Mr. King served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra…
Chief Legal Officer
With over 18 years of experience, Amy Mendel is responsible for all aspects of Vor’s legal and intellectual property matters. Amy has spent the last five years establishing and managing legal, contracts, and intellectual property for early-stage biopharma companies, such as Accent Therapeutics, Rheos…
Chief People Officer
Tania Philipp, Chief People Officer, brings more than 15 years’ experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experience team that will help Vor achieve its objectives….
Chief Regulatory and Quality Officer
Dr. Pietrusko has directed the worldwide approval of more than 30 new products. He also led the submission and approval strategies for more than 30 new drug applications (NDAs), supplemental NDAs, biologics license applications and marketing authorization applications in multiple therapeutic areas. As an…
Senior Vice President, Program and Alliance Management
Dr. Veit Schmelmer oversees the management of Vor’s clinical research programs, working with cross-functional teams and external collaborators to advance the company’s engineered hematopoietic stem cell (eHSC) platform. Dr. Schmelmer has over 25 years of experience leading the development of novel therapies for cancer,…
Chief Medical Officer
Dr. Christopher Slapak has more than 20 years of leadership experience in oncology drug development. Prior to being appointed as CMO, Dr. Slapak served as Vor’s Interim Chief Medical Officer as part of his work as an independent consultant advising on scientific and medical…
